1
|
Klein JL, Adams SM, De Moura AF, Alves Filho DC, Maidana FM, Brondani IL, Cocco JM, Rodrigues LDS, Pizzuti LAD, Da Silva MB. Productive performance of beef cows subjected to different nutritional levels in the third trimester of gestation. Animal 2020; 15:100089. [PMID: 33712220 DOI: 10.1016/j.animal.2020.100089] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/22/2019] [Revised: 09/20/2020] [Accepted: 09/21/2020] [Indexed: 11/30/2022] Open
Abstract
In general, calf production occurs in less intensive systems. The limitation of nutrients during the gestation phase of beef cows can have negative impacts on the consequent productivity of females. Therefore, this study aimed to evaluate the effects of nutritional levels in the third trimester of pregnancy on the productive performance of beef cows kept in a natural pasture (NP). Eighty-three Charolais × Nelore cows were used, ranging in age from 4 to 12 years, which were divided according to their nutritional levels during the third trimester of pregnancy: NP, cows supplemented with 100% of their energy and protein requirements (SP100) and cows supplemented with 150% of their energy and protein requirements (SP150). The experimental design was completely randomized with three treatments and a varied number of repetitions. The SP100 and SP150 cows presented better body condition at calving (2.92 and 2.99 vs 2.81 points) and at the start of the breeding season (2.90 and 2.95 vs 2.80 points) than did NP cows. The nutritional level of the cows in the third trimester of gestation did not influence the blood metabolite concentrations. The plasma levels of albumin and total proteins were 3.11 and 8.18 g/dl, respectively. Glucose and cholesterol showed values of 74.96 and 166.50 mg/dl. The lowest concentration of blood metabolites was observed in the first postpartum weeks. The SP100 and SP150 cows showed faster follicular growth and, consequently, a higher percentage of females with ovulatory follicles at 21 days postpartum than did NP cows (45.68, 41.11, and 11.00%, respectively). The SP150 cows had a higher pregnancy rate (40.74%), total calf production (295.88 kg/cow), and consequently, offspring sale value. An increased nutritional level in the third trimester of pregnancy improves the postpartum metabolic condition and productive efficiency of beef cows kept on NP.
Collapse
Affiliation(s)
- J L Klein
- Federal University of Santa Maria, Santa Maria, Rio Grande do Sul, Brazil.
| | - S M Adams
- Federal University of Santa Maria, Santa Maria, Rio Grande do Sul, Brazil
| | - A F De Moura
- Federal University of Santa Maria, Santa Maria, Rio Grande do Sul, Brazil
| | - D C Alves Filho
- Department of Animal Science, Federal University of Santa Maria, Santa Maria, Rio Grande do Sul, Brazil
| | - F M Maidana
- Federal University of Santa Maria, Santa Maria, Rio Grande do Sul, Brazil
| | - I L Brondani
- Department of Animal Science, Federal University of Santa Maria, Santa Maria, Rio Grande do Sul, Brazil
| | - J M Cocco
- Federal University of Santa Maria, Santa Maria, Rio Grande do Sul, Brazil
| | - L D S Rodrigues
- Federal University of Santa Maria, Santa Maria, Rio Grande do Sul, Brazil
| | - L A D Pizzuti
- Department of Animal Science, Federal University of Santa Maria, Santa Maria, Rio Grande do Sul, Brazil
| | - M B Da Silva
- Federal University of Santa Maria, Santa Maria, Rio Grande do Sul, Brazil
| |
Collapse
|
2
|
Klein JL, Cooper DT. Deviant Cyber-Sexual Activities in Young Adults: Exploring Prevalence and Predictions Using In-Person Sexual Activities and Social Learning Theory. Arch Sex Behav 2019; 48:619-630. [PMID: 29987544 DOI: 10.1007/s10508-018-1251-2] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 07/09/2016] [Revised: 03/15/2018] [Accepted: 05/31/2018] [Indexed: 06/08/2023]
Abstract
Technology has shifted some human interactions to the virtual world. For many young adults, sexual encounters now occur through virtual means, as social media, picture exchanges, sexually explicit Web sites, and video chatting have become popular alternative outlets for these activities to occur. This study used the self-report responses of 812 undergraduate students (282 men and 530 women), collected from an online survey. In addition to using 10 personal demographic control variables, this study used five sexual activity/relationship characteristics (number of sexual partners, relationship status, age to first use pornography, frequency of sexual activity/intercourse, and frequency of masturbation), and the four constructs of Akers' social learning theory (identified as differential association, differential reinforcement, imitation/modeling, and definitions favorable) to predict a seven-item count of deviant cyber-sexual activities, and two measures of "sexting" behaviors. Gender, self-esteem, sexual orientation, race, and religion were strongly significant predictors in the models, but Akers' four elements of social learning performed the strongest in predicting the two measures of sexting and the overall deviant cyber-sexual activities scale. This finding indicates that peer associations and peer reinforcements have a strong influence on individuals' willingness to engage in deviant cyber-sexual activities. This study explored different avenues for young adults' engagement in sexual deviancy and the results suggest that sexual behaviors performed in-person may not be the strongest predictors of online sexual behavior.
Collapse
Affiliation(s)
- Jennifer L Klein
- Division of Criminal Justice, Department of Social Sciences, University of Texas at Tyler, 3900 University Blvd., Tyler, TX, 75799, USA.
| | - Danielle Tolson Cooper
- Henry C. Lee College of Criminal Justice and Forensic Sciences, University of New Haven, West Haven, CT, USA
| |
Collapse
|
3
|
Lawrence CHD, Waseem S, Newsholme W, Klein JL. Trueperella bernardiae: an unusual cause of septic thrombophlebitis in an injection drug user. New Microbes New Infect 2018; 26:89-91. [PMID: 30310680 PMCID: PMC6178208 DOI: 10.1016/j.nmni.2018.09.001] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/15/2018] [Revised: 08/30/2018] [Accepted: 09/04/2018] [Indexed: 11/25/2022] Open
Abstract
The clinical spectrum of human disease caused by Trueperella bernardiae is poorly described, partly as a result of historical difficulties with microbial identification. With the introduction of powerful new technologies, such as matrix-assisted desorption ionization–time of flight mass spectrometry, into routine microbiology laboratories, new insights into diseases caused by such organisms are being made. Here we report a case of septic thrombophlebitis with bacteraemia caused by this organism, together with a retrospective description of laboratory isolation of this organism over a period of 6 years in a hospital in London, UK.
Collapse
Affiliation(s)
- C H D Lawrence
- Department of Infection, St Thomas' Hospital, London, UK
| | - S Waseem
- Department of Surgery, St Thomas' Hospital, London, UK
| | - W Newsholme
- Department of Infection, St Thomas' Hospital, London, UK
| | - J L Klein
- Department of Infection, St Thomas' Hospital, London, UK
| |
Collapse
|
4
|
Affiliation(s)
- Bun Song Lee
- Department of Accounting, Economics and Finance, University of Arkansas-Fort Smith, Fort Smith, USA
| | - Jennifer L. Klein
- Department of Economics, University of Colorado Boulder, UCB 256, Boulder, CO 80309-0256
| |
Collapse
|
5
|
Wu NC, Wong W, Ho KE, Chu VC, Rizo A, Davonport S, Kelly D, Makar R, Jassem J, Duchnowska R, Biernat W, Radecka B, Fujita T, Klein JL, Stonecypher M, Ohta S, Juhl H, Weidler JM, Bates M, Press MF. Abstract P1-03-03: High concordance of ER, PR, HER2 and Ki67 by central IHC and FISH with mRNA measurements by GeneXpert® breast cancer stratifier assay. Cancer Res 2017. [DOI: 10.1158/1538-7445.sabcs16-p1-03-03] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Current methods for the assessment of ER, PR, Her2, and Ki67 using FFPE tissues are hard to standardize and difficult to perform in Low and Middle Income Countries (LMIC). The GeneXpert® breast cancer stratifier assay (RUO) (BC Strat) is a cartridge-based, RT-qPCR assay of ESR1, PGR, ERBB2, and MKi67 mRNAs using FFPE specimens. The assay is fast (<2 hours, including <10 minutes of hands-on time) and easy to perform.
The aims of this study were: 1) to evaluate the concordance of BC Strat using different IHC antibodies and scoring methods in a preliminary dataset (Part I); and 2) to assess concordance between BC Strat and high quality standard methods in an expanded dataset (Part II).
Methods
Part I: IHC Antibody Variability
To assess BC Strat concordance with various IHC antibodies, 155 invasive ductal carcinoma blocks were sourced from 3 sites. Twenty-four adjacent slide sections from each block were prepared and shipped to different labs for BC Strat analysis(Cepheid) or IHC and FISH testing. Table 1 summarizes the IHC antibodies and scoring methods used in each reference lab.
Table 1:IHC antibodies and scoring methods used in reference labs Antibody for IHClabIHC scoringERSP1MPLNAutomated (Aperio)ER6F11Path IncAutomated (Aperio)ER6F11USCManualPRIE2MPLNAutomated (Aperio)PR16Path IncAutomated (Aperio)PRPGR636USCManualHer2*4B5MPLNAutomated (Aperio)Her2*HercepTestUSCManualKi6730-9MPLNAutomated (Aperio)Ki67MIB1Path IncAutomated (Aperio)Ki67MIB1USCManual*HER2 FISH (all with PathVysion kit) was performed at USC
Part II: Concordance Study
522 invasive ductal carcinoma FFPE samples were sourced from 5 sites. All BC Strat analysis was performed at Cepheid and all IHC and FISH was performed in the Press laboratory at USC. Overall percent agreement (OPA), positive percent agreement (PPA), and negative percent agreement (NPA) between BC Strat and IHC were determined.
Results
Part I: IHC Antibody Variability
Table 2 summarizes the OPA for BC Strat analysis and IHC performed with different IHC antibodies and scoring methods. Slightly better concordance for ER and PR was observed between the BC Strat and the IHC methods performed at USC. Discordant IHC results were also observed among the reference labs' standard methodologies.
Table 2: Overall Percent Agreement between IHC and BC Strat Reference LabOPA with BC StratERMPLN92%ERPath Inc96%ERUSC98%PRMPLN84%PRPath Inc83%PRUSC87%Her2*MPLN*93%Her2*USC*91%Ki67MPLN75%Ki67Path Inc67%Ki67USC81%*for IHC 2+(equivocal), FISH HER2/CEP17 ratio was examined
Part II: Concordance Study
Of the 522 samples tested, 499 (96%) yielded valid results for both BC Strat and IHC (IHC and FISH for Her2). OPA between BC Strat and IHC was 98% for ESR1, 91% for PGR, 93% for ERBB2 (IHC and FISH, 97% for Her2 IHC excluding IHC2+), and 81% for MKi67.
Conclusion
BC Strat assay measurements for ESR1, PGR, ERBB2 and MKi67 mRNA expression in FFPE breast tumor tissues are highly concordant with IHC and FISH performed by high quality reference labs. Further investigations using clinical outcomes from independent studies including prospective-retrospective clinical trials are in progress.
Citation Format: Wu NC, Wong W, Ho KE, Chu VC, Rizo A, Davonport S, Kelly D, Makar R, Jassem J, Duchnowska R, Biernat W, Radecka B, Fujita T, Klein JL, Stonecypher M, Ohta S, Juhl H, Weidler JM, Bates M, Press MF. High concordance of ER, PR, HER2 and Ki67 by central IHC and FISH with mRNA measurements by GeneXpert® breast cancer stratifier assay [abstract]. In: Proceedings of the 2016 San Antonio Breast Cancer Symposium; 2016 Dec 6-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2017;77(4 Suppl):Abstract nr P1-03-03.
Collapse
Affiliation(s)
- NC Wu
- Cepheid, Sunnyavale, CA; Keck School of Medicine/University of Southern California, Los Angeles, CA; Geneuity/MPLN, Maryville, TN; Oregon Health & Science University, Portland, OR; Medical University of Gdansk, Gdansk, Poland; Military Institute of Medicine, Warsaw, Poland; Oncology Center, Opole, Poland; Tokyo Medical University, Ibaraki, Japan; Indivumed GmbH, Humburg, Germany; Josai University, Sakado, Japan
| | - W Wong
- Cepheid, Sunnyavale, CA; Keck School of Medicine/University of Southern California, Los Angeles, CA; Geneuity/MPLN, Maryville, TN; Oregon Health & Science University, Portland, OR; Medical University of Gdansk, Gdansk, Poland; Military Institute of Medicine, Warsaw, Poland; Oncology Center, Opole, Poland; Tokyo Medical University, Ibaraki, Japan; Indivumed GmbH, Humburg, Germany; Josai University, Sakado, Japan
| | - KE Ho
- Cepheid, Sunnyavale, CA; Keck School of Medicine/University of Southern California, Los Angeles, CA; Geneuity/MPLN, Maryville, TN; Oregon Health & Science University, Portland, OR; Medical University of Gdansk, Gdansk, Poland; Military Institute of Medicine, Warsaw, Poland; Oncology Center, Opole, Poland; Tokyo Medical University, Ibaraki, Japan; Indivumed GmbH, Humburg, Germany; Josai University, Sakado, Japan
| | - VC Chu
- Cepheid, Sunnyavale, CA; Keck School of Medicine/University of Southern California, Los Angeles, CA; Geneuity/MPLN, Maryville, TN; Oregon Health & Science University, Portland, OR; Medical University of Gdansk, Gdansk, Poland; Military Institute of Medicine, Warsaw, Poland; Oncology Center, Opole, Poland; Tokyo Medical University, Ibaraki, Japan; Indivumed GmbH, Humburg, Germany; Josai University, Sakado, Japan
| | - A Rizo
- Cepheid, Sunnyavale, CA; Keck School of Medicine/University of Southern California, Los Angeles, CA; Geneuity/MPLN, Maryville, TN; Oregon Health & Science University, Portland, OR; Medical University of Gdansk, Gdansk, Poland; Military Institute of Medicine, Warsaw, Poland; Oncology Center, Opole, Poland; Tokyo Medical University, Ibaraki, Japan; Indivumed GmbH, Humburg, Germany; Josai University, Sakado, Japan
| | - S Davonport
- Cepheid, Sunnyavale, CA; Keck School of Medicine/University of Southern California, Los Angeles, CA; Geneuity/MPLN, Maryville, TN; Oregon Health & Science University, Portland, OR; Medical University of Gdansk, Gdansk, Poland; Military Institute of Medicine, Warsaw, Poland; Oncology Center, Opole, Poland; Tokyo Medical University, Ibaraki, Japan; Indivumed GmbH, Humburg, Germany; Josai University, Sakado, Japan
| | - D Kelly
- Cepheid, Sunnyavale, CA; Keck School of Medicine/University of Southern California, Los Angeles, CA; Geneuity/MPLN, Maryville, TN; Oregon Health & Science University, Portland, OR; Medical University of Gdansk, Gdansk, Poland; Military Institute of Medicine, Warsaw, Poland; Oncology Center, Opole, Poland; Tokyo Medical University, Ibaraki, Japan; Indivumed GmbH, Humburg, Germany; Josai University, Sakado, Japan
| | - R Makar
- Cepheid, Sunnyavale, CA; Keck School of Medicine/University of Southern California, Los Angeles, CA; Geneuity/MPLN, Maryville, TN; Oregon Health & Science University, Portland, OR; Medical University of Gdansk, Gdansk, Poland; Military Institute of Medicine, Warsaw, Poland; Oncology Center, Opole, Poland; Tokyo Medical University, Ibaraki, Japan; Indivumed GmbH, Humburg, Germany; Josai University, Sakado, Japan
| | - J Jassem
- Cepheid, Sunnyavale, CA; Keck School of Medicine/University of Southern California, Los Angeles, CA; Geneuity/MPLN, Maryville, TN; Oregon Health & Science University, Portland, OR; Medical University of Gdansk, Gdansk, Poland; Military Institute of Medicine, Warsaw, Poland; Oncology Center, Opole, Poland; Tokyo Medical University, Ibaraki, Japan; Indivumed GmbH, Humburg, Germany; Josai University, Sakado, Japan
| | - R Duchnowska
- Cepheid, Sunnyavale, CA; Keck School of Medicine/University of Southern California, Los Angeles, CA; Geneuity/MPLN, Maryville, TN; Oregon Health & Science University, Portland, OR; Medical University of Gdansk, Gdansk, Poland; Military Institute of Medicine, Warsaw, Poland; Oncology Center, Opole, Poland; Tokyo Medical University, Ibaraki, Japan; Indivumed GmbH, Humburg, Germany; Josai University, Sakado, Japan
| | - W Biernat
- Cepheid, Sunnyavale, CA; Keck School of Medicine/University of Southern California, Los Angeles, CA; Geneuity/MPLN, Maryville, TN; Oregon Health & Science University, Portland, OR; Medical University of Gdansk, Gdansk, Poland; Military Institute of Medicine, Warsaw, Poland; Oncology Center, Opole, Poland; Tokyo Medical University, Ibaraki, Japan; Indivumed GmbH, Humburg, Germany; Josai University, Sakado, Japan
| | - B Radecka
- Cepheid, Sunnyavale, CA; Keck School of Medicine/University of Southern California, Los Angeles, CA; Geneuity/MPLN, Maryville, TN; Oregon Health & Science University, Portland, OR; Medical University of Gdansk, Gdansk, Poland; Military Institute of Medicine, Warsaw, Poland; Oncology Center, Opole, Poland; Tokyo Medical University, Ibaraki, Japan; Indivumed GmbH, Humburg, Germany; Josai University, Sakado, Japan
| | - T Fujita
- Cepheid, Sunnyavale, CA; Keck School of Medicine/University of Southern California, Los Angeles, CA; Geneuity/MPLN, Maryville, TN; Oregon Health & Science University, Portland, OR; Medical University of Gdansk, Gdansk, Poland; Military Institute of Medicine, Warsaw, Poland; Oncology Center, Opole, Poland; Tokyo Medical University, Ibaraki, Japan; Indivumed GmbH, Humburg, Germany; Josai University, Sakado, Japan
| | - JL Klein
- Cepheid, Sunnyavale, CA; Keck School of Medicine/University of Southern California, Los Angeles, CA; Geneuity/MPLN, Maryville, TN; Oregon Health & Science University, Portland, OR; Medical University of Gdansk, Gdansk, Poland; Military Institute of Medicine, Warsaw, Poland; Oncology Center, Opole, Poland; Tokyo Medical University, Ibaraki, Japan; Indivumed GmbH, Humburg, Germany; Josai University, Sakado, Japan
| | - M Stonecypher
- Cepheid, Sunnyavale, CA; Keck School of Medicine/University of Southern California, Los Angeles, CA; Geneuity/MPLN, Maryville, TN; Oregon Health & Science University, Portland, OR; Medical University of Gdansk, Gdansk, Poland; Military Institute of Medicine, Warsaw, Poland; Oncology Center, Opole, Poland; Tokyo Medical University, Ibaraki, Japan; Indivumed GmbH, Humburg, Germany; Josai University, Sakado, Japan
| | - S Ohta
- Cepheid, Sunnyavale, CA; Keck School of Medicine/University of Southern California, Los Angeles, CA; Geneuity/MPLN, Maryville, TN; Oregon Health & Science University, Portland, OR; Medical University of Gdansk, Gdansk, Poland; Military Institute of Medicine, Warsaw, Poland; Oncology Center, Opole, Poland; Tokyo Medical University, Ibaraki, Japan; Indivumed GmbH, Humburg, Germany; Josai University, Sakado, Japan
| | - H Juhl
- Cepheid, Sunnyavale, CA; Keck School of Medicine/University of Southern California, Los Angeles, CA; Geneuity/MPLN, Maryville, TN; Oregon Health & Science University, Portland, OR; Medical University of Gdansk, Gdansk, Poland; Military Institute of Medicine, Warsaw, Poland; Oncology Center, Opole, Poland; Tokyo Medical University, Ibaraki, Japan; Indivumed GmbH, Humburg, Germany; Josai University, Sakado, Japan
| | - JM Weidler
- Cepheid, Sunnyavale, CA; Keck School of Medicine/University of Southern California, Los Angeles, CA; Geneuity/MPLN, Maryville, TN; Oregon Health & Science University, Portland, OR; Medical University of Gdansk, Gdansk, Poland; Military Institute of Medicine, Warsaw, Poland; Oncology Center, Opole, Poland; Tokyo Medical University, Ibaraki, Japan; Indivumed GmbH, Humburg, Germany; Josai University, Sakado, Japan
| | - M Bates
- Cepheid, Sunnyavale, CA; Keck School of Medicine/University of Southern California, Los Angeles, CA; Geneuity/MPLN, Maryville, TN; Oregon Health & Science University, Portland, OR; Medical University of Gdansk, Gdansk, Poland; Military Institute of Medicine, Warsaw, Poland; Oncology Center, Opole, Poland; Tokyo Medical University, Ibaraki, Japan; Indivumed GmbH, Humburg, Germany; Josai University, Sakado, Japan
| | - MF Press
- Cepheid, Sunnyavale, CA; Keck School of Medicine/University of Southern California, Los Angeles, CA; Geneuity/MPLN, Maryville, TN; Oregon Health & Science University, Portland, OR; Medical University of Gdansk, Gdansk, Poland; Military Institute of Medicine, Warsaw, Poland; Oncology Center, Opole, Poland; Tokyo Medical University, Ibaraki, Japan; Indivumed GmbH, Humburg, Germany; Josai University, Sakado, Japan
| |
Collapse
|
6
|
Sharma H, Sarker SJ, Lambourne JR, Fhogartaigh CN, Price NM, Klein JL. The selective outpatient treatment of adults with imported falciparum malaria: a prospective cohort study. QJM 2016; 109:181-6. [PMID: 26025694 DOI: 10.1093/qjmed/hcv113] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 03/19/2015] [Indexed: 11/12/2022] Open
Abstract
BACKGROUND Current UK malaria treatment guidelines recommend admission for all patients diagnosed with falciparum malaria. However, evidence suggests that certain patients are at lower risk of severe malaria and death and may be managed as outpatients. AIM To prospectively assess the risk of post-treatment severe falciparum malaria in selected cases managed as outpatients. The readmission rate and treatment tolerability were assessed as secondary outcomes. DESIGN Prospective cohort study. METHODS Adults (>15 years old) diagnosed with falciparum malaria between May 2008 and July 2012 were selected for outpatient treatment using locally defined clinical and laboratory indicators based on known risk factors for severity and death. Treatment outcomes were assessed in clinic or by telephone 4-6 weeks after treatment. RESULTS 269 adults were diagnosed with falciparum malaria on blood film between May 2008 and July 2012. Of 255 eligible participants, 106 patients were offered ambulatory treatment, of which 95 completed the study. The severe malaria rate was 0% (95% confidence interval (CI) 0-3.8%) and the readmission rate was 5.3% (95% CI 1.7-11.9) in the outpatient group. In addition, 10.6% (95% CI 5.2-18.7%) of outpatients reported drug-related side effects. CONCLUSIONS The outpatient treatment of selected cases of falciparum malaria is effective in our high volume UK setting. We recommend adopting a similar approach to managing this infection in other non-endemic settings where immediate access to specialist advice is available.
Collapse
Affiliation(s)
- H Sharma
- From the Department of Infectious Diseases, Guy's and St Thomas' NHS Foundation Trust, Westminster Bridge Road, London, SE1 7EH, UK and
| | - S-J Sarker
- Centre for Experimental Cancer Medicine, Barts Cancer Institute, Queen Mary University of London, Old Anatomy Building, Charterhouse Square, London, EC1M 6BQ, UK
| | - J R Lambourne
- From the Department of Infectious Diseases, Guy's and St Thomas' NHS Foundation Trust, Westminster Bridge Road, London, SE1 7EH, UK and
| | - C N Fhogartaigh
- From the Department of Infectious Diseases, Guy's and St Thomas' NHS Foundation Trust, Westminster Bridge Road, London, SE1 7EH, UK and
| | - N M Price
- From the Department of Infectious Diseases, Guy's and St Thomas' NHS Foundation Trust, Westminster Bridge Road, London, SE1 7EH, UK and
| | - J L Klein
- From the Department of Infectious Diseases, Guy's and St Thomas' NHS Foundation Trust, Westminster Bridge Road, London, SE1 7EH, UK and
| |
Collapse
|
7
|
Abstract
Mandatory bacteraemia reporting was extended to include Escherichia coli from June 2011. The purpose of this study was to investigate whether the success seen in reducing meticillin-resistant Staphylococcus aureus infection rates could be duplicated with E. coli. All cases of E. coli bacteraemia occurring at our Trust in 2010 were reviewed. There were 216 episodes of E. coli bacteraemia, of which 63% were community-acquired. Only 19% had a potentially preventable cause identified, the majority (71%) of whom had urinary catheter-associated bacteraemia. These data must be kept in mind should targets to reduce E. coli bacteraemia be set in the future.
Collapse
Affiliation(s)
- J Underwood
- Guy's and St Thomas' NHS Foundation Trust, London, UK.
| | | | | |
Collapse
|
8
|
Aurelle D, Baker AJ, Bottin L, Brouat C, Caccone A, Chaix A, Dhakal P, Ding Y, Duplantier JM, Fiedler W, Fietz J, Fong Y, Forcioli D, Freitas TRO, Gunnarsson GH, Haddrath O, Hadziabdic D, Hauksdottir S, Havill NP, Heinrich M, Heinz T, Hjorleifsdottir S, Hong Y, Hreggvidsson GO, Huchette S, Hurst J, Kane M, Kane NC, Kawakami T, Ke W, Keith RA, Klauke N, Klein JL, Kun JFJ, Li C, Li GQ, Li JJ, Loiseau A, Lu LZ, Lucas M, Martins-Ferreira C, Mokhtar-Jamaï K, Olafsson K, Pampoulie C, Pan L, Pooler MR, Ren JD, Rinehart TA, Roussel V, Santos MO, Schaefer HM, Scheffler BE, Schmidt A, Segelbacher G, Shen JD, Skirnisdottir S, Sommer S, Tao ZR, Taubert R, Tian Y, Tomiuk J, Trigiano RN, Ungerer MC, Van Wormhoudt A, Wadl PA, Wang DQ, Weis-Dootz T, Xia Q, Yuan QY. Permanent Genetic Resources added to the Molecular Ecology Resources Database 1 February 2010-31 March 2010. Mol Ecol Resour 2010; 10:751-4. [PMID: 21565086 DOI: 10.1111/j.1755-0998.2010.02871.x] [Citation(s) in RCA: 25] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
Abstract
This article documents the addition of 228 microsatellite marker loci to the Molecular Ecology Resources Database. Loci were developed for the following species: Anser cygnoides, Apodemus flavicollis, Athene noctua, Cercis canadensis, Glis glis, Gubernatrix cristata, Haliotis tuberculata, Helianthus maximiliani, Laricobius nigrinus, Laricobius rubidus, Neoheligmonella granjoni, Nephrops norvegicus, Oenanthe javanica, Paramuricea clavata, Pyrrhura orcesi and Samanea saman. These loci were cross-tested on the following species: Apodemus sylvaticus, Laricobius laticollis and Laricobius osakensis (a proposed new species currently being described).
Collapse
Affiliation(s)
-
- Aix-Marseille Université, Centre d'Océanologie de Marseille, CNRS-UMR 6540 DIMAR, rue de la Batterie des Lions, 13007 Marseille, France
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
9
|
Klein JL, Macdonald RFP, Vaillancourt G, Ahearn WH, Dube WV. Teaching Discrimination of Adult Gaze Direction to Children with Autism. Res Autism Spectr Disord 2009; 3:42-49. [PMID: 20046922 PMCID: PMC2751861 DOI: 10.1016/j.rasd.2008.03.006] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/28/2023]
Abstract
Three young children diagnosed with autism did not reliably locate objects in the environment on the basis of an adult's gaze shifts. A training program designed to teach gaze following used the activation of remote controlled mechanical toys as both prompts and consequences. Over several training sessions, toy activation was progressively delayed following the adult's gaze-shift cues. All of the children eventually came to anticipate the toy activation and locate the target object on the basis of the adult's gaze-shift cue alone. Discrimination of another person's gaze direction is discussed in relation to joint attention deficits in children with autism.
Collapse
|
10
|
Otter JA, Klein JL, Watts TL, Kearns AM, French GL. Identification and control of an outbreak of ciprofloxacin-susceptible EMRSA-15 on a neonatal unit. J Hosp Infect 2007; 67:232-9. [PMID: 17933423 DOI: 10.1016/j.jhin.2007.07.024] [Citation(s) in RCA: 23] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/17/2007] [Accepted: 07/27/2007] [Indexed: 11/17/2022]
Abstract
We report the identification and control of an outbreak of a ciprofloxacin-susceptible strain of UK epidemic meticillin-resistant Staphylococcus aureus (EMRSA)-15 on a neonatal unit (NNU). All babies were screened for MRSA on admission using ciprofloxacin-containing media which did not detect the outbreak strain. The first identified case was a premature baby who developed MRSA bacteraemia with associated tibial osteomyelitis and multiple subcutaneous abscesses. The outbreak strain was subsequently identified in the nasopharyngeal secretions of a second child who was not clinically infected. Screening of all patients on the NNU using non-ciprofloxacin-media identified two other colonised babies. All four patient isolates were EMRSA-15, spa type t022, SCCmec IV, Panton-Valentine leucocidin (PVL) negative, indistinguishable by pulsed-field gel electrophoresis and susceptible to all non-beta-lactam antimicrobials tested. The outbreak strain was cultured from four of 48 environmental sites in a communal milk-expressing room. Unsupervised movement of mothers to and from the milk-expressing room may have contributed to the outbreak. Control measures included cohort isolation of affected babies, improved environmental cleaning, increased emphasis on hand hygiene and education of mothers. Ciprofloxacin-containing media should be used with caution for MRSA screening in settings where ciprofloxacin-susceptible strains (including community-associated MRSA) are increasing in prevalence.
Collapse
Affiliation(s)
- J A Otter
- Infection and Immunology Delivery Unit, St Thomas' Hospital and King's College London, London, UK
| | | | | | | | | |
Collapse
|
11
|
Narreddy S, Mellon-Reppen S, Abidi MH, Klein JL, Peres E, Heilbrun LK, Smith D, Alangaden G, Chandrasekar PH. Non-bacterial infections in allogeneic non-myeloablative stem cell transplant recipients. Transpl Infect Dis 2007; 9:3-10. [PMID: 17313464 DOI: 10.1111/j.1399-3062.2006.00172.x] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/30/2022]
Abstract
Data on non-bacterial infections during allogeneic non-myeloablative hematopoietic stem cell transplantation (HSCT) are widely different. We evaluated data on 48 consecutive patients who received a conditioning regimen with fludarabine and cyclophosphamide (73%) or fludarabine and total body irradiation (27%) and then underwent allogeneic non-myeloablative HSCT. Cytomegalovirus (CMV) infection was common and occurred in 48% of patients; 3 patients developed CMV disease, and all survived. CMV reactivation was found to be common with both conditioning regimens in our patient population. Invasive aspergillosis occurred in 4 patients (8%) and 3 died. Other serious non-bacterial infections were uncommon. Review of the available literature on non-myeloablative HSCT suggests that the frequency and type of opportunistic infections vary considerably.
Collapse
Affiliation(s)
- S Narreddy
- Division of Infectious Diseases, Detroit Medical Center, Karmanos Cancer Institute, Wayne State University School of Medicine, Detroit, Michigan, USA
| | | | | | | | | | | | | | | | | |
Collapse
|
12
|
Abstract
Evidence strongly suggests that antibiotic prophylaxis should not be used routinely for transoesophageal echocardiography for any indication.
Collapse
|
13
|
Fabre C, Criddle J, Nolder D, Klein JL. Recrudescence of imported falciparum malaria after quinine therapy: potential drug interaction with phenytoin. Trans R Soc Trop Med Hyg 2005; 99:871-3. [PMID: 16099004 DOI: 10.1016/j.trstmh.2005.06.009] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/03/2004] [Revised: 06/10/2005] [Accepted: 06/11/2005] [Indexed: 11/24/2022] Open
Abstract
Quinine remains a reliable treatment for falciparum malaria in most parts of the world. We report recrudescence of imported Plasmodium falciparum malaria following quinine treatment in the context of concurrent phenytoin use. Supported by a subtherapeutic quinine level, we hypothesise that a drug interaction with phenytoin may compromise the efficacy of quinine in the treatment of malaria.
Collapse
Affiliation(s)
- C Fabre
- Department of Paediatric Emergency Medicine, Guy's and St Thomas' NHS Foundation Trust, Lambeth Wing, St Thomas' Hospital, London SE1 7EH, UK
| | | | | | | |
Collapse
|
14
|
Affiliation(s)
- A Minassian
- Department of Infection, St. Thomas' Hospital, London, UK SE1 7EH
| | | | | |
Collapse
|
15
|
Klein JL, Hamm C, Dansey RD, Karanes C, Abella E, Cassells L, Peters WP, Baynes RD. High-dose chemotherapy and CD34-selected peripheral blood progenitor cell transplantation for patients with breast cancer metastatic to bone and/or bone marrow. Bone Marrow Transplant 2001; 28:1023-9. [PMID: 11781611 DOI: 10.1038/sj.bmt.1703274] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/24/2001] [Accepted: 08/09/2001] [Indexed: 11/09/2022]
Abstract
Fifty women with breast cancer metastatic to bone or bone marrow involvement on light microscopy at the time of initial evaluation were treated with high-dose chemotherapy (HDC) and peripheral blood progenitor cell (PBPC) transplantation with CD34(+) cell selection using the Isolex 300i system. All patients received induction chemotherapy. PBPC were mobilized with chemotherapy and granulocyte colony-stimulating factor. The median CD34(+) progenitor purity was 94.7% (range 72-98.7%) and recovery 38.4% (range 21-60%). Forty-eight hours after HDC with cyclophosphamide, cisplatin and carmustine, PBPC were reinfused. Median time to neutrophil count >0.5 x 10(9)/l was 9 (range 9-12) days and to platelet transfusion independence 11 (4-30) days. These data demonstrate that selected CD34(+) PBPCs allow rapid hematologic reconstitution after HDC. During follow-up, 23% of patients developed herpes zoster. Two patients developed cytomegalovirus infections. Three patients developed fungal infections. The development of these infections was not associated with steroid use but appeared more frequently in patients with diabetes mellitus. Seventy-four per cent of patients received steroids for pulmonary toxicity. Treatment-related mortality was 4%. Progression-free survival and overall survival at 35 months was 22.4% and 40.5%, with a median of 11.4 months and 15.4 months, respectively.
Collapse
Affiliation(s)
- J L Klein
- Barbara Ann Karmanos Cancer Center, Wayne State University School of Medicine, Division of Hematology and Oncology, Detroit, MI, USA
| | | | | | | | | | | | | | | |
Collapse
|
16
|
Abstract
Rifampin is the most potent drug used in the treatment of disease due to Mycobacterium kansasii. A 69-bp fragment of rpoB, the gene that encodes the beta subunit of the bacterial RNA polymerase, was sequenced and found to be identical in five rifampin-susceptible clinical isolates of M. kansasii. This sequence showed 87% homology with the Mycobacterium tuberculosis gene, with an identical deduced amino acid sequence. In contrast, missense mutations were detected in the same fragment amplified from five rifampin-resistant isolates. A rifampin-resistant strain generated in vitro also harbored an rpoB gene missense mutation that was not present in the parent isolate. All mutations detected (in codons 513, 526, and 531) have previously been described in rifampin-resistant M. tuberculosis isolates. Rifampin MICs determined by E-test were <1 mg/liter for all rifampin-susceptible isolates and >256 mg/liter for all rifampin-resistant ones. In addition, four of the five rifampin-resistant isolates were also resistant to rifabutin. We have thus shown a strong association between rpoB gene missense mutations and rifampin resistance in M. kansasii. Although our results are derived from a small number of isolates and confirmation with larger numbers would be useful, they strongly suggest that mutations within rpoB form the molecular basis of rifampin resistance in this species.
Collapse
Affiliation(s)
- J L Klein
- Department of Infection, Guy's, King's and St. Thomas' School of Medicine, St. Thomas' Hospital, London SE1 7EH, United Kingdom.
| | | | | |
Collapse
|
17
|
Baynes RD, Dansey RD, Klein JL, Hamm C, Campbell M, Abella E, Peters WP. High-dose chemotherapy and hematopoietic stem cell transplantation for breast cancer: past or future? Semin Oncol 2001; 28:377-88. [PMID: 11498831 DOI: 10.1016/s0093-7754(01)90131-9] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
Abstract
Given that each year in the United States 180,000 new cases of breast cancer are diagnosed, with about 44,000 women succumbing to the disease, and that breast cancer is the second leading cause of cancer-related death in women, it is clear that existing therapy fails a large number of patients. Recently, a number of novel strategies have been developed in attempts to improve survival. These include agents used at very high dose requiring stem cell support. High-dose chemotherapy (HDC) with hematopoietic stem cell transplantation (HSCT), most frequently in the form of peripheral blood progenitor cell transplantation (PBPCT), is an highly active treatment approach in appropriate patients and the current data relating to this modality will be reviewed here. This article will attempt to place the recent randomized studies in perspective, to highlight the strengths and limitations of the data, and to offer some thoughts on future directions for the field.
Collapse
Affiliation(s)
- R D Baynes
- Bone Marrow Transplant Program, Barbara Ann Karmanos Cancer Institute, Department of Medicine, Wayne State University, Detroit, MI 48201, USA
| | | | | | | | | | | | | |
Collapse
|
18
|
Abstract
There is strong circumstantial evidence that multiple sclerosis (MS) is an autoimmune disease. Nonspecific immunosuppressive therapy has not been successful in altering the natural course of the illness. Bone marrow transplantation has heretofore been a radical therapy used in patients with life-threatening malignancies but has potential as a treatment for human autoimmunity. In MS there have been no controlled studies. We report here four patients with MS undergoing bone marrow transplantation with 6-48 months of follow-up. In three this was carried out for co-existing malignancy and in one as an experimental treatment for MS using the patient's unaffected identical twin as a donor. The limited outcome that can be evaluated in these patients supports further experimentation into this treatment modality in MS patients with poor prognostic indications.
Collapse
Affiliation(s)
- P Mandalfino
- Department of Clinical Neurological Sciences, University of Western Ontario, London, Canada
| | | | | | | | | | | |
Collapse
|
19
|
Vita JA, Yeung AC, Winniford M, Hodgson JM, Treasure CB, Klein JL, Werns S, Kern M, Plotkin D, Shih WJ, Mitchel Y, Ganz P. Effect of cholesterol-lowering therapy on coronary endothelial vasomotor function in patients with coronary artery disease. Circulation 2000; 102:846-51. [PMID: 10952951 DOI: 10.1161/01.cir.102.8.846] [Citation(s) in RCA: 89] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
BACKGROUND Improved endothelial function may contribute to the beneficial effects of cholesterol-lowering therapy. METHODS AND RESULTS In this randomized, double-blind study, we compared the effect of 6 months of simvastatin (40 mg/d) treatment with that of placebo on coronary endothelial vasomotor function in 60 patients with coronary artery disease. Simvastatin lowered LDL-cholesterol by 40+/-12% from 130+/-28 mg/dL (P<0.001). Peak intracoronary acetylcholine infusion produced epicardial coronary constriction at baseline in both the simvastatin (-17+/-13%) and placebo (-24+/-16%) groups. After treatment, acetylcholine produced less constriction in both groups (-12+/-19% and -15+/-14%, respectively, P=0.97). The increase in coronary blood flow during infusion of the peak dose of substance P was blunted at baseline in both the simvastatin (42+/-50%) and placebo (55+/-71%) groups, reflecting impaired endothelium-dependent dilation of coronary microvessels. After treatment, the flow increase was 82+/-81% in the simvastatin group and 63+/-53% in the placebo group (P=0.16). CONCLUSIONS Six months of cholesterol-lowering therapy has no significant effect on coronary endothelial vasomotor function in the study population of patients with coronary artery disease and mildly elevated cholesterol levels. These findings suggest that the effects of cholesterol lowering on endothelial function are more complex than previously thought.
Collapse
Affiliation(s)
- J A Vita
- Boston University School of Medicine, Boston, MA, USA.
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
20
|
Baynes RD, Dansey RD, Klein JL, Karanes C, Cassells L, Abella E, Wei WZ, Galy A, Du W, Wood G, Peters WP. High-dose chemotherapy and autologous stem cell transplantation for breast cancer. Cancer Invest 2000; 18:440-55. [PMID: 10834029 DOI: 10.3109/07357900009032816] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]
Affiliation(s)
- R D Baynes
- Bone Marrow Transplant Program, Barbara Ann Karmanos Cancer Institute, Wayne State University, Detroit, Michigan, USA
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
21
|
Klein JL, Rey PM, Dansey RD, Karanes C, Du W, Abella E, Cassells L, Hamm C, Peters WP, Baynes RD. Cardiac sequelae of doxorubicin and paclitaxel as induction chemotherapy prior to high-dose chemotherapy and peripheral blood progenitor cell transplantation in women with high-risk primary or metastatic breast cancer. Bone Marrow Transplant 2000; 25:1047-52. [PMID: 10828864 DOI: 10.1038/sj.bmt.1702394] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Abstract
Doxorubicin plus paclitaxel has been shown to be an active regimen for metastatic breast cancer and is now frequently used as adjuvant therapy for high-risk primary breast cancer. Initial studies reported a higher than expected rate of cardiac toxicity with this regimen. We studied 105 patients with either high-risk primary breast cancer or metastatic breast cancer who were treated with doxorubicin (60 mg/m2) and 3-h infusions of paclitaxel (175 mg/m2) cycled every 3 weeks. Patients received three cycles of chemotherapy for high-risk primary or four cycles for metastatic disease. Patients then proceeded to high-dose chemotherapy (HDC) (STAMP I cyclophosphamide, cisplatin and carmustine) and peripheral blood progenitor cell transplantation (PBPCT). Patients underwent radionuclide multi-gated angiograms (MUGA) before and following induction chemotherapy and following HDC. During induction chemotherapy 40 (38%) of the patients had a reduction in left ventricular ejection fraction (LVEF). Fourteen had a decrease of 20% or greater and two were mildly symptomatic from CHF. There was additional reduction in the LVEF after HDC with a median value for LVEF of 59% (range, 20-78%). During HDC 10 patients developed clinical signs of congestive heart failure (CHF). Five patients responded to diuretic therapy and did not require any additional treatment. Four patients responded to vasodilation and/or digoxin with improvement in cardiac function. A clinically significant decrease in cardiac function was found in a small number of patients after induction chemotherapy and HDC with PBPCT. The majority of the patients tolerated this regimen without problems. Although there was a decline in LVEF as measured by radionuclide MUGA this did not prevent the majority of patients from proceeding with HDC. Bone Marrow Transplantation (2000).
Collapse
Affiliation(s)
- J L Klein
- Barbara Ann Karmanos Cancer Center, Wayne State University School of Medicine, Division of Hematology and Oncology, Detroit, Michigan, USA
| | | | | | | | | | | | | | | | | | | |
Collapse
|
22
|
Peters WP, Dansey RD, Klein JL, Baynes RD. High-dose chemotherapy and peripheral blood progenitor cell transplantation in the treatment of breast cancer. Oncologist 2000; 5:1-13. [PMID: 10706643 DOI: 10.1634/theoncologist.5-1-1] [Citation(s) in RCA: 34] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022] Open
Abstract
Each year in the USA, 180,000 new cases of breast cancer are diagnosed and about 44,000 women die of the disease. Current primary treatment consists of adjuvant chemotherapy and hormone therapy, and statistics show that combination chemotherapy favorably influences the outcomes in both node-negative and node-positive primary disease. However, a significant number of breast cancer patients succumb to the disease, and nearly every patient diagnosed with metastatic breast cancer will be dead within five years. High-dose chemotherapy (HDC) and peripheral blood progenitor cell transplantation (PBPCT) are based upon laboratory and clinical observations of the ability to modify growth properties of quiescent and replicating cancer cells. A large number of HDC and PBPCT regimens have been evaluated for treatment of metastatic breast cancer, and recent autologous bone marrow transplantation data indicate that three HDC regimens (CPB, CTCb and cytoxan and thiotepa) predominate. Unfortunately, negative media coverage surrounding and subsequent to the presentation of preliminary findings reported at the May 1999 American Society of Clinical Oncologists, that were not allowed adequate follow-up time for full analysis of treatment results, has had a detrimental effect on the ability to conduct trials in this area. Several randomized trials have been conducted in both the metastatic and high risk primary disease settings. Thorough analysis of these studies indicates an evaluable improvement in favor of HDC and PBPCT in three of the four randomized studies performed in metastatic breast cancer and two of the four high risk primary studies. Also, initial evaluations found that quality of life appeared comparable in patients receiving either HDC or not. Each randomized trial studied asks a different question and, depending on the intensity of HDC regimen, the intensity and duration of the standard dose chemotherapy control and the schedule of events in relation to induction chemotherapy, the outcomes may be quite variable. Still, certain general trends are indentifiable. HDC alone will not completely cure breast cancer and should be considered as part of an overall therapeutic plan. In some of these studies, significantly longer follow-up is required before definitive analysis can be completed.
Collapse
Affiliation(s)
- W P Peters
- Bone Marrow Transplant Program, Barbara Ann Karmanos Cancer Institute, Wayne State University, Detroit, Michigan 48201, USA
| | | | | | | |
Collapse
|
23
|
Klein JL, Garvie DC, Tulloh R, Marsh M, MacMahon E. Fatal chickenpox: negative electron microscopy of vesicular samples may be misleading. Arch Dis Child 2000; 82:183. [PMID: 10702113 PMCID: PMC1718203 DOI: 10.1136/adc.82.2.183a] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
|
24
|
Klein JL, Roberts JD, George MD, Kurtzberg J, Breton P, Chermann JC, Olden K. Swainsonine protects both murine and human haematopoietic systems from chemotherapeutic toxicity. Br J Cancer 1999; 80:87-95. [PMID: 10389983 PMCID: PMC2363022 DOI: 10.1038/sj.bjc.6690326] [Citation(s) in RCA: 27] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022] Open
Abstract
The haematopoietic system is sensitive to cytotoxic damage and is often the site of dose-limiting toxicity. We previously reported that swainsonine, an inhibitor of protein glycosylation, reduced the bone marrow toxicity resulting from a single dose of anticancer drugs in otherwise healthy mice. However, more important questions are (1) can swainsonine protect tumour-bearing mice without interfering with the anti-tumour effects of the drugs, and (2) can swainsonine stimulate haematopoietic activity of human, as well as murine, bone marrow. We demonstrate here that swainsonine protects C57BL/6 mice bearing melanoma-derived tumours from cyclophosphamide-induced toxicity without interfering with the drug's ability to inhibit tumour growth. Similar results were obtained in vivo with 3'-azido-3'-deoxythymidine (AZT), a myelosuppressive agent often used in therapy for acquired immune deficiency syndrome. Swainsonine increased both total bone marrow cellularity and the number of circulating white blood cells in mice treated with doses of AZT that typically lead to severe myelosuppression. Swainsonine also increased the number of erythroid and myeloid colony forming cells (CFCs) in short-term cultures of murine bone marrow, restoring the number of progenitor cells to the control level in the presence of AZT doses that reduced CFCs by 80%. With respect to the sensitivity of human haematopoietic cells to swainsonine, we show that swainsonine protected human myeloid progenitor cells from AZT toxicity in vitro. These results suggest that swainsonine may be useful as an adjuvant in several types of human chemotherapy.
Collapse
Affiliation(s)
- J L Klein
- Laboratory of Molecular Carcinogenesis, National Institute of Environmental Health Sciences, National Institutes of Health, Research Triangle Park, NC 27709, USA
| | | | | | | | | | | | | |
Collapse
|
25
|
Wingard JR, Nash RA, Przepiorka D, Klein JL, Weisdorf DJ, Fay JW, Zhu J, Maher RM, Fitzsimmons WE, Ratanatharathorn V. Relationship of tacrolimus (FK506) whole blood concentrations and efficacy and safety after HLA-identical sibling bone marrow transplantation. Biol Blood Marrow Transplant 1999; 4:157-63. [PMID: 9923414 DOI: 10.1053/bbmt.1998.v4.pm9923414] [Citation(s) in RCA: 17] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Abstract
A randomized clinical trial comparing tacrolimus with cyclosporine, both with short-course methotrexate, as prophylaxis against graft-vs.-host disease (GVHD) in allogeneic HLA-matched sibling bone marrow transplant patients was conducted. Cyclosporine was dosed to achieve a target concentration range between 150 and 450 ng/mL during the first 8 weeks after transplant. For tacrolimus, the target concentration range was 10-30 ng/mL during the first 8 weeks after transplant. A gradual tapering schedule of 20% per month during months 3-6 was then conducted for patients in both treatment arms. The efficacy of the immunosuppressive regimen was determined by the rate of acute GVHD grades II-IV The toxicity of the immunosuppressive regimen was determined by the occurrence of the creatinine exceeding 2 mg/dL, the creatinine doubling the baseline value, or the necessity for hemodialysis. Correlations between blood concentrations and efficacy and toxicity parameters were assessed. For both tacrolimus and cyclosporine, increasing blood concentrations were associated with greater renal dysfunction. For cyclosporine, there was a nonsignificant trend to an increased incidence of grades II-IV acute GVHD with lower cyclosporine blood concentrations (<300 ng/mL). In contrast, there did not appear to be a relationship between the blood concentrations of tacrolimus and the occurrence of acute GVHD. This suggests that optimization of efficacy while minimizing the risk for nephrotoxicity could be achieved by dosing tacrolimus to a targeted range between 10 and 20 ng/mL.
Collapse
Affiliation(s)
- J R Wingard
- University of Florida College of Medicine, Gainesville 32610-0277, USA
| | | | | | | | | | | | | | | | | | | |
Collapse
|
26
|
Abstract
OBJECTIVES although Mycobacterium kansasii infection has long been endemic in the U.K., the disease burden and characteristics of infection in the HIV-seropositive population has not been well documented. This study addresses these issues in an inner city population that comprises a quarter of all cases of acquired immunodeficiency syndrome (AIDS) reported in the U.K. METHODS retrospective review of case notes from two inner London specialist HIV Units. RESULTS twenty-nine cases of M. kansasii infection were identified, with case notes available for review in 26. Ten had pulmonary disease and nine had disseminated infection: a further seven patients appeared simply to be colonized (two respiratory and five gastrointestinal): M. kansasii was isolated from stool in over a third (nine of 26) of cases. Disseminated M. kansasii infection occurred in 0.44% of AIDS cases seen in our two units and all isolates were resistant to isoniazid ion vitro. A clinical response achieved in 11 of the 13 patients with M. kansasii-related disease who received anti-mycobacterial therapy. All four patients who relapsed following initial clinical response to therapy had received sub-optimal treatment. CONCLUSIONS the incidence of disseminated M. kansasii infection in HIV-infected individuals in the U.K. is similar to that seen in those from high prevalence regions of the U.S.A., and anti-mycobacterial therapy leads to a clinical response in the majority of patients with HIV and M. kansasii co-infection. The frequent isolation of M. kansasii from the stool suggests that the gastrointestinal tract may be a significant source of disseminated infection.
Collapse
Affiliation(s)
- J L Klein
- Department of Genitourinary Medicine, St. Mary's Hospital, London, UK
| | | | | | | | | |
Collapse
|
27
|
Ratanatharathorn V, Nash RA, Przepiorka D, Devine SM, Klein JL, Weisdorf D, Fay JW, Nademanee A, Antin JH, Christiansen NP, van der Jagt R, Herzig RH, Litzow MR, Wolff SN, Longo WL, Petersen FB, Karanes C, Avalos B, Storb R, Buell DN, Maher RM, Fitzsimmons WE, Wingard JR. Phase III study comparing methotrexate and tacrolimus (prograf, FK506) with methotrexate and cyclosporine for graft-versus-host disease prophylaxis after HLA-identical sibling bone marrow transplantation. Blood 1998; 92:2303-14. [PMID: 9746768] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/08/2023] Open
Abstract
We report the results of a phase III open-label, randomized, multicenter trial comparing tacrolimus/methotrexate to cyclosporine/methotrexate for graft-versus-host disease (GVHD) prophylaxis after HLA-identical sibling marrow transplantation in patients with hematologic malignancy. The primary objective of this study was to compare the incidence of moderate to severe (grade II-IV) acute GVHD. Secondary objectives were to compare the relapse rate, disease-free survival, overall survival, and the incidence of chronic GVHD. Patients were stratified according to age (<40 v >/=40) and for male recipients of a marrow graft from an alloimmunized female. There was a significantly greater proportion of patients with advanced disease randomized to tacrolimus arm (P = . 02). The incidence of grade II-IV acute GVHD was significantly lower in patients who received tacrolimus than patients in the cyclosporine group (31.9% and 44.4%, respectively; P = .01). The incidence of grade III-IV acute GVHD was similar, 17.1% in cyclosporine group and 13.3% in the tacrolimus group. There was no difference in the incidence of chronic GVHD between the tacrolimus and the cyclosporine group (55.9% and 49.4%, respectively; P = .8). However, there was a significantly higher proportion of patients in the cyclosporine group who had clinical extensive chronic GVHD (P = . 03). The relapse rates of the two groups were similar. The patients in the cyclosporine arm had a significantly better 2-year disease-free survival and overall survival than patients in the tacrolimus arm, 50.4% versus 40.5% (P = .01) and 57.2% versus 46.9% (P = .02), respectively. The significant difference in the overall and disease-free survival was largely the result of the patients with advanced disease, 24.8% with tacrolimus versus 41.7% with cyclosporine (P = .006) and 20.4% with tacrolimus versus 28% with cyclosporine (P = .007), respectively. There was a higher frequency of deaths from regimen-related toxicity in patients with advanced disease who received tacrolimus. There was no difference in the disease-free and overall survival in patients with nonadvanced disease. These results show the superiority of tacrolimus/methotrexate over cyclosporine/methotrexate in the prevention of grade II-IV acute GVHD with no difference in disease-free or overall survival in patients with nonadvanced disease. The survival disadvantage in advanced disease patients receiving tacrolimus warrants further investigation.
Collapse
Affiliation(s)
- V Ratanatharathorn
- University of Michigan, Ann Arbor; Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
28
|
Roberts JD, Klein JL, Palmantier R, Dhume ST, George MD, Olden K. The role of protein glycosylation inhibitors in the prevention of metastasis and therapy of cancer. Cancer Detect Prev 1998; 22:455-62. [PMID: 9727627 DOI: 10.1046/j.1525-1500.1998.00054.x] [Citation(s) in RCA: 20] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
Abstract
Oligosaccharide moieties of cell-surface glycoproteins are thought to be involved in recognition events during cancer metastasis and invasion. Swainsonine, an inhibitor of the Golgi alpha-mannosidase II, has been shown to block pulmonary colonization by tumor cells and stimulate components of the immune system. Swainsonine also abrogates much of the toxicity of chemotherapeutic agents and stimulates bone marrow hematopoietic progenitor cells, suggesting additional therapeutic applications. We are currently characterizing the ability of swainsonine to modify cell growth in human and murine bone marrow progenitor cells. Furthermore, we are examining crucial steps in metastasis that depend upon cell surface molecules that play a role in cell-matrix interactions. Our work shows that tumor cell adhesion to collagen IV in vitro is rapidly stimulated by cis-polyunsaturated fatty acids and is dependent on protein kinase C activity. We are investigating the hypothesis that integrins are critical components of this adhesion and are examining potential signal transduction pathways that lead to the modulation of cell adhesion.
Collapse
Affiliation(s)
- J D Roberts
- Laboratory of Molecular Carcinogenesis, National Institute of Environmental Health Sciences, Research Triangle Park, NC 27709, USA
| | | | | | | | | | | |
Collapse
|
29
|
Wolff BG, Bolton J, Baum R, Chetanneau A, Pecking A, Serafini AN, Fischman AJ, Hoover HC, Klein JL, Wynant GE, Subramanian R, Goroff DK, Hanna MG. Radioimmunoscintigraphy of recurrent, metastatic, or occult colorectal cancer with technetium Tc 99m 88BV59H21-2V67-66 (HumaSPECT-Tc), a totally human monoclonal antibody. Patient management benefit from a phase III multicenter study. Dis Colon Rectum 1998; 41:953-62. [PMID: 9715149 DOI: 10.1007/bf02237380] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/08/2023]
Abstract
PURPOSE The study contained herein was undertaken to evaluate the accuracy of radiolabeled human monoclonal antibody, 88BV59H21-2V67-66 (88BV59 or HumaSPECT-Tc), in predicting disease resectability in presurgical subjects with recurrent, metastatic, or occult colorectal carcinoma. METHODS A total of 219 patients with disease visualized on computed tomographic scan (recurrent or metastatic disease) or with negative or equivocal computed tomographic scan and rising carcinoembryonic antigen serum levels (occult group) received technetium Tc99m-labeled 88BV59 intravenously. Planar and single photon emission computed tomograhic images were obtained 14 to 20 hours postinfusion, before surgery. The ability of computed tomographic and HumaSPECT-Tc imaging to define the extent of disease and to predict resectability was evaluated based on surgical and histopathologic results. RESULTS In patients with recurrent or metastatic disease (170 evaluable patients), the accuracy of predicting nonresectability of disease was significantly greater (P < 0.001) for HumaSPECT-Tc than for computed tomography (60 vs 29 percent). Computed tomography understaged 41 percent of patients believed to have resectable disease compared with 27 percent for HumaSPECT-Tc (P < 0.001). In occult disease patients (29 computed tomographic and 28 HumaSPECT-Tc evaluable patients), the overall accuracy of predicting resectability/nonresectability was 6 percent for HumaSPECT-Tc compared with 24 percent from computed tomography. Administration of HumaSPECT-Tc had no effect on monoclonal antibody-based in vitro diagnostic assays. Only a single patient demonstrated an anti-antibody response (90 ng/ml) at nine weeks postinfusion. CONCLUSION HumaSPECT-Tc was more accurate than computed tomography in determining disease resectability in patients with metastatic, recurrent, or occult cancer. The addition of HumaSPECT-Tc imaging can play a significant role in patient management decisions.
Collapse
Affiliation(s)
- B G Wolff
- Department of Colorectal and General Surgery, Mayo Clinic, Rochester, Minnesota, USA
| | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
30
|
Klein JL, Brown TJ, Dean GL, Gant V. Mycobacterium genavense infection in a UK based patient with AIDS: diagnosis using molecular techniques. Sex Transm Infect 1998; 74:306. [PMID: 9924483] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/10/2023] Open
|
31
|
Klein JL, Brown TJ, Dean GL, Gant V. Mycobacterium genavense infection in a UK based patient with AIDS: diagnosis using molecular techniques. Sex Transm Infect 1998. [DOI: 10.1136/sti.74.4.306-a] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022] Open
|
32
|
King SB, Williams DO, Chougule P, Klein JL, Waksman R, Hilstead R, Macdonald J, Anderberg K, Crocker IR. Endovascular beta-radiation to reduce restenosis after coronary balloon angioplasty: results of the beta energy restenosis trial (BERT). Circulation 1998; 97:2025-30. [PMID: 9610532 DOI: 10.1161/01.cir.97.20.2025] [Citation(s) in RCA: 244] [Impact Index Per Article: 9.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/07/2023]
Abstract
BACKGROUND In the porcine overstretch injury model of restenosis, endovascular beta-radiation reduces neointima formation. To determine whether this therapy could be applied to patients with coronary artery disease, a special device was developed to allow delivery of 12 encapsulated 90Sr/Y sources, measuring a total of 30 mm, to various sites within the coronary arterial tree. This study was designed to evaluate the feasibility of the delivery of 12, 14, or 16 Gy at 2 mm after balloon angioplasty of stenoses of native coronary vessels. METHODS AND RESULTS Delivery of beta-radiation was attempted in 23 patients after successful balloon angioplasty. Source delivery was successful in 21 of the 23 patients (91%). There was no in-hospital or 30-day morbidity or mortality. Follow-up quantitative coronary arteriography in 20 patients demonstrated a late loss of 0.05 mm, a late loss index of 4%, and a restenosis rate of 15%. The use of the beta-emitter 90Sr/Y significantly reduced treatment time and operator exposure compared with previous trials with the gamma-emitter 192Ir. CONCLUSIONS In this study, the administration of endovascular beta-radiation after angioplasty was safe and feasible and substantially altered the postangioplasty late lumen loss, resulting in a lower-than-expected rate of restenosis. On the basis of these encouraging results, a multicenter, randomized trial with operators and patients blinded to treatment assignment is planned.
Collapse
Affiliation(s)
- S B King
- Andreas Gruentzig Cardiovascular Center, Division of Cardiology, Emory University School of Medicine, Atlanta, GA, USA.
| | | | | | | | | | | | | | | | | |
Collapse
|
33
|
Klein JL, Millman GC. Prospective, hospital based study of fever in children in the United Kingdom who had recently spent time in the tropics. BMJ 1998; 316:1425-6. [PMID: 9572752 PMCID: PMC28540 DOI: 10.1136/bmj.316.7142.1425] [Citation(s) in RCA: 30] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 02/07/2023]
Affiliation(s)
- J L Klein
- Children's Services Directorate, Northwick Park and St Mark's NHS Trust, Harrow, Middlesex HA1 3UJ.
| | | |
Collapse
|
34
|
Serafini AN, Klein JL, Wolff BG, Baum R, Chetanneau A, Pecking A, Fischman AJ, Hoover HC, Wynant GE, Subramanian R, Goroff DK, Hanna MG. Radioimmunoscintigraphy of recurrent, metastatic, or occult colorectal cancer with technetium 99m-labeled totally human monoclonal antibody 88BV59: results of pivotal, phase III multicenter studies. J Clin Oncol 1998; 16:1777-87. [PMID: 9586891 DOI: 10.1200/jco.1998.16.5.1777] [Citation(s) in RCA: 17] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
PURPOSE To assess the performance and potential clinical impact of a totally human monoclonal antibody, 88BV59 (HumaSPECT) (INTRACEL, Corp, Rockville, MD), in 202 assessable presurgical patients with recurrent, metastatic, or occult colorectal cancer. METHODS 88BV59, labeled with technetium Tc 99m (99mTc) (HumaSPECT-Tc), was injected intravenously, and planar and single photon emission tomography (SPECT) images were obtained 14 to 20 hours postinjection. Surgical and pathologic verification of tumor were used as the standard against which the performance of HumaSPECT-Tc imaging and computed tomography (CT) analysis were evaluated. RESULTS All patients entered onto the recurrent disease study had at least one tumor site defined on CT. The sensitivity of HumaSPECT-Tc in those CT-positive patients was 87%. The specificity of HumaSPECT-Tc was 57% compared with 17% for CT and the difference was statistically significant (P < .001). The diagnostic information provided by HumaSPECT-Tc significantly (P < .001) improved the accuracy of the identification of resectable and nonresectable disease over that of CT (80% v 62%). HumaSPECT-Tc scans resulted in a significant (P < .001) reduction versus CT in terms of the proportion of patients understaged (27% v 41%) and overstaged (4% v 26%). In patients with occult disease (increasing carcinoembryonic antigen [CEA] titer, negative diagnostic work-up, negative CT), HumaSPECT-Tc correctly identified disease in 15 of 22 (68%) patients. HumaSPECT-Tc images provided additional clinical data that would have affected patient management decisions in 40 of 202 (19.8%) patients. In 365 patients who received 88BV59, only a single detectable human anti-human antibody (HAHA) response (90 ng/mL) at 9 weeks postinfusion was observed. CONCLUSION HumaSPECT-Tc can provide important and accurate information about the presence and location of disease in patients with a high clinical suspicion of metastatic or recurrent colorectal cancer and either positive (known disease) or negative (occult disease) CT scans.
Collapse
Affiliation(s)
- A N Serafini
- Division of Nuclear Medicine, University of Miami School of Medicine, FL, USA
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
35
|
Klein JL, Hoff JG, Peifer JW, Folks R, Cooke CD, King SB, Garcia EV. A quantitative evaluation of the three dimensional reconstruction of patients' coronary arteries. Int J Card Imaging 1998; 14:75-87. [PMID: 9617637 DOI: 10.1023/a:1005903705300] [Citation(s) in RCA: 35] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 02/07/2023]
Abstract
BACKGROUND Through extensive training and experience angiographers learn to mentally reconstruct the three dimensional (3D) relationships of the coronary arterial branches. Graphic computer technology can assist angiographers to more quickly visualize the coronary 3D structure from limited initial views and then help to determine additional helpful views by predicting subsequent angiograms before they are obtained. METHODS A new computer method for facilitating 3D reconstruction and visualization of human coronary arteries was evaluated by reconstructing biplane left coronary angiograms from 30 patients. The accuracy of the reconstruction was assessed in two ways: 1) by comparing the vessel's centerlines of the actual angiograms with the centerlines of a 2D projection of the 3D model projected into the exact angle of the actual angiogram; and 2) by comparing two 3D models generated by different simultaneous pairs on angiograms. The inter- and intraobserver variability of reconstruction were evaluated by mathematically comparing the 3D model centerlines of repeated reconstructions. RESULTS The average absolute corrected displacement of 14,662 vessel centerline points in 2D from 30 patients was 1.64 +/- 2.26 mm. The average corrected absolute displacement of 3D models generated from different biplane pairs was 7.08 +/- 3.21 mm. The intraobserver variability of absolute 3D corrected displacement was 5.22 +/- 3.39 mm. The interobserver variability was 6.6 +/- 3.1 mm. CONCLUSIONS The centerline analyses show that the reconstruction algorithm is mathematically accurate and reproducible. The figures presented in this report put these measurement errors into clinical perspective showing that they yield an accurate representation of the clinically relevant information seen on the actual angiograms. These data show that this technique can be clinically useful by accurately displaying in three dimensions the complex relationships of the branches of the coronary arterial tree.
Collapse
Affiliation(s)
- J L Klein
- Emory University School of Medicine, Atlanta, GA, USA.
| | | | | | | | | | | | | |
Collapse
|
36
|
Boccuzzi SJ, Weintraub WS, Kosinski AS, Roehm JB, Klein JL. Aggressive lipid lowering in postcoronary angioplasty patients with elevated cholesterol (the Lovastatin Restenosis Trial). Am J Cardiol 1998; 81:632-6. [PMID: 9514463 DOI: 10.1016/s0002-9149(97)00980-6] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/06/2023]
Abstract
A substudy of the Lovastatin Restenosis Trial in patients with elevated cholesterol (>200 mg/dl) showed no evidence of an effect of aggressive lipid lowering on restenosis, confirming the results of the main trial.
Collapse
Affiliation(s)
- S J Boccuzzi
- Department of Medicine, Emory University School of Medicine, Atlanta, Georgia, USA
| | | | | | | | | |
Collapse
|
37
|
Wingard JR, Nash RA, Ratanatharathorn V, Fay JW, Klein JL, Przepiorka D, Maher RM, Devine SM, Boswell G, Bekersky I, Fitzsimmons W. Lack of interaction between tacrolimus (FK506) and methotrexate in bone marrow transplant recipients. Bone Marrow Transplant 1997; 20:49-51. [PMID: 9232256 DOI: 10.1038/sj.bmt.1700839] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/04/2023]
Abstract
Tacrolimus (FK506) is a macrolide lactone effective in the control of graft-versus-host disease (GVHD). An interaction between high-dose methotrexate and a macrolide antibiotic (pristinamycin) leading to prolonged methotrexate exposure has been described. Because a randomized prospective trial comparing tacrolimus with cyclosporine (both in combination with methotrexate) following allogeneic BMT showed the tacrolimus plus methotrexate regimen to be more effective in prevention of GVHD, we assessed methotrexate pharmacokinetics in a subgroup of the participants of this trial to evaluate the possibility that an interaction of FK506 and methotrexate was the explanation for the clinical findings. Mean and median methotrexate levels at various time-points after the day 1 and 6 methotrexate doses were comparable in the tacrolimus and cyclosporine cohorts and were elevated in only three of 70 study patients. Area under the curve (AUC) concentrations were also similar after the day 1 and 6 methotrexate doses. Thus, no significant interaction between tacrolimus and methotrexate is apparent and the differences in efficacy between tacrolimus and cyclosporine are unlikely to be attributable to pharmacologic interactions with methotrexate.
Collapse
Affiliation(s)
- J R Wingard
- University of Florida College of Medicine, Department of Medicine, Gainesville 32610-0277, USA
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
38
|
Price DA, Klein JL, Fisher M, Main J, Bingham JS, Coker RJ. Potential role for granulocyte-macrophage colony-stimulating factor in the treatment of HIV-associated cryptococcal meningitis. AIDS 1997; 11:693-4. [PMID: 9108959] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/04/2023]
|
39
|
Copelan EA, Ceselski SK, Ezzone SA, Lasky LC, Penza SL, Bechtel TP, Klein JL, Hehmeyer DM, Scholl MD, Marshall DD, Elder PJ, Risley GL, Avalos BR. Mobilization of peripheral-blood progenitor cells with high-dose etoposide and granulocyte colony-stimulating factor in patients with breast cancer, non-Hodgkin's lymphoma, and Hodgkin's disease. J Clin Oncol 1997; 15:759-65. [PMID: 9053502 DOI: 10.1200/jco.1997.15.2.759] [Citation(s) in RCA: 40] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/03/2023] Open
Abstract
PURPOSE We analyzed the safety and effectiveness of high-dose etoposide (2 g/m2) followed by granulocyte colony-stimulating factor (G-CSF) as a peripheral-blood progenitor cell (PBPC) mobilization regimen and assessed extent of tumor reduction in patients with breast cancer, non-Hodgkin's lymphoma (NHL), and Hodgkin's disease (HD). PATIENTS AND METHODS One hundred sixty-nine consecutive patients who eventually underwent PBPC transplantation received treatment with high-dose etoposide (2 g/m2) followed by daily G-CSF (5 microg/kg). RESULTS This mobilization method was effective in nearly all patients. No patients died of mobilization-related complications. A 50% reduction in tumor size was seen in 19% of assessable patients with breast cancer, 44% of those with NHL, and 38% of those with HD. Hematopoietic recovery (HR) following transplantation occurred in all patients. Patients with > or = 4 x 10(6) CD34+ cells/kg engrafted with neutrophils at a median of 9 days after transplant and patients with at least 1.2 x 10(6) CD34+/CD33- cells/kg achieved platelet recovery at a median of 15 days. CONCLUSION Etoposide plus G-CSF is an effective and safe method for mobilization of PBPCs. Etoposide is an effective agent in tumor reduction in NHL and HD and is less effective in breast cancer. The substantially lower incidence of prior exposure to this agent compared with cyclophosphamide favors its use.
Collapse
Affiliation(s)
- E A Copelan
- Department of Internal Medicine, The Ohio State University, Columbus 43210, USA.
| | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
40
|
|
41
|
Seemungal B, Klein JL. Respiratory grey case. Int J STD AIDS 1996; 7:322. [PMID: 8894820 DOI: 10.1258/0956462961918194] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/02/2023]
|
42
|
Klein JL, Fickenscher H, Holliday JE, Biesinger B, Fleckenstein B. Herpesvirus saimiri immortalized gamma delta T cell line activated by IL-12. The Journal of Immunology 1996. [DOI: 10.4049/jimmunol.156.8.2754] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/01/2023]
Abstract
Abstract
IL-12 is a novel heterodimeric cytokine important for the regulation and differentiation of lymphocytes and NK cells. Like other cytokines, IL-12 mediates its biologic activity through high-affinity receptors expressed on responsive cells. To date, a large number of receptors for IL-12 have been found only on PBMC following activation with PHA or IL-2. To gain further knowledge of the IL-12R complex and the IL-12 signal transduction pathway in cytotoxic T cells, we studied a number of human T cell lines that had been transformed to permanent growth with Herpesvirus saimiri, an oncogenic virus of nonhuman primates. This paper reports the expression of IL-12R on a human gamma delta T cell line that responds to IL-12 with enhanced cytolytic activity and increased expression of cytolytic effector molecules granzyme B and perforin. Using these T cells as a model of IL-12 signal transduction, we confirmed that these events involve members of the Janus kinase family of nonreceptor tyrosine kinases JAK2, TYK2, and signal transducer and activator of transcription 4.
Collapse
Affiliation(s)
- J L Klein
- Division of Hematology and Oncology, Barbara Ann Karmanos Cancer Institute, Wayne State University, Detroit, MI 48201, USA
| | - H Fickenscher
- Division of Hematology and Oncology, Barbara Ann Karmanos Cancer Institute, Wayne State University, Detroit, MI 48201, USA
| | - J E Holliday
- Division of Hematology and Oncology, Barbara Ann Karmanos Cancer Institute, Wayne State University, Detroit, MI 48201, USA
| | - B Biesinger
- Division of Hematology and Oncology, Barbara Ann Karmanos Cancer Institute, Wayne State University, Detroit, MI 48201, USA
| | - B Fleckenstein
- Division of Hematology and Oncology, Barbara Ann Karmanos Cancer Institute, Wayne State University, Detroit, MI 48201, USA
| |
Collapse
|
43
|
Klein JL, Boccuzzi SJ, Treasure CB, Manoukian SV, Vogel RA, Beauman GJ, Fischman D, Savage MP, Weintaub WS. Performance standards and edge detection with computerized quantitative coronary arteriography. The Lovastatin Restenosis Trial Group. Am J Cardiol 1996; 77:815-22. [PMID: 8623732 DOI: 10.1016/s0002-9149(97)89174-6] [Citation(s) in RCA: 17] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/31/2023]
Abstract
Quantitative coronary angiography (QCA) has become an important tool for evaluating coronary angiograms. Many methodologic factors, such as the choice of frame to analyze, the selection of the "normal," segment and the method of edge detection used may affect the results of QCA. The sequential steps in performing QCA, including a comparison of visual and automated edge-detection methodologies, were evaluated using 12 precision-drilled phantoms and 20 patient films. Normal diameter, minimal lumen diameter, and diameter stenosis were measured. In the phantom studies, the measurements from both visual and automated systems correlated well with the true measurements of the phantoms and between systems (all r values >0.92). To study the difference between methodologies on QCA results as influenced by the choice of frame and normal segment analyzed, the patient films were analyzed independently in 3 separate rounds of interpretation. In round 1, each system's operator individually chose frames and normal segments for analysis. In round 2, both systems analyzed the same preselected frames, but independently chose normal segments. In round 3, both systems analyzed the same preselected normal segments and frames. The intersystem correlations between visual and automatic systems for rounds 1, 2, and 3 were: normal diameter, r = 0.25, r = 0.37, and r = 0.75, respectively; minimal lumen diameter, r = 0.79, r = 0.86, and r = 0.85, respectively; and diameter stenosis, r = 0.65, r = 0.73, and r = 0.87, respectively. The manual edge-detection and automated edge-detection systems used in this study are reasonably accurate and consistent on phantom studies. In patient studies, the nonautomated processes (choice of frame and normal segment for analysis) produced significant differences in the QCA results, thus illustrating that operator-dependent factors other than edge detection are very important in QCA.
Collapse
Affiliation(s)
- J L Klein
- Emory University, Atlanta, Georgia, USA
| | | | | | | | | | | | | | | | | |
Collapse
|
44
|
Klein JL, Fickenscher H, Holliday JE, Biesinger B, Fleckenstein B. Herpesvirus saimiri immortalized gamma delta T cell line activated by IL-12. J Immunol 1996; 156:2754-60. [PMID: 8609393] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 01/31/2023]
Abstract
IL-12 is a novel heterodimeric cytokine important for the regulation and differentiation of lymphocytes and NK cells. Like other cytokines, IL-12 mediates its biologic activity through high-affinity receptors expressed on responsive cells. To date, a large number of receptors for IL-12 have been found only on PBMC following activation with PHA or IL-2. To gain further knowledge of the IL-12R complex and the IL-12 signal transduction pathway in cytotoxic T cells, we studied a number of human T cell lines that had been transformed to permanent growth with Herpesvirus saimiri, an oncogenic virus of nonhuman primates. This paper reports the expression of IL-12R on a human gamma delta T cell line that responds to IL-12 with enhanced cytolytic activity and increased expression of cytolytic effector molecules granzyme B and perforin. Using these T cells as a model of IL-12 signal transduction, we confirmed that these events involve members of the Janus kinase family of nonreceptor tyrosine kinases JAK2, TYK2, and signal transducer and activator of transcription 4.
Collapse
Affiliation(s)
- J L Klein
- Division of Hematology and Oncology, Barbara Ann Karmanos Cancer Institute, Wayne State University, Detroit, MI 48201, USA
| | | | | | | | | |
Collapse
|
45
|
Klein JL, Avalos BR, Belt P, Taylor CA, Ezzone SA, Scholl MD, Fisher J, Young D, Copelan EA. Bone marrow engraftment following unrelated donor transplantation utilizing busulfan and cyclophosphamide preparatory chemotherapy. Bone Marrow Transplant 1996; 17:479-83. [PMID: 8722342] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/01/2023]
Abstract
Two major problems of unrelated donor transplantation have been an increased incidence of GVHD and graft failure. Even with HLA identity by microlymphocytotoxicity assay and non-reactive MLC, URD marrow transplant recipients have a higher incidence of graft rejection and GVHD. The preparative regimen busulfan 16 mg/kg and cyclophosphamide 120 mg/kg (BuCy2) has been shown to be at least as effective in preparation of recipients with CML of HLA-identical sibling grafts as cyclophosphamide and total body irradiation (Cy/TBI). However, concern about a high rejection rate in URD transplants has prevented most centers from using BuCy2 in this setting. From March 1990 to March 1994, 26 patients underwent URD transplantation following preparation with BuCy2. Patients received either standard cyclosporine and methotrexate or cyclosporine and methylprednisolone for GVHD prophylaxis. Two patients died on day 16 and 20 without evidence of hematopoietic engraftment. Of the 24 patients evaluable for engraftment, 23 (96%) had evidence of donor engraftment defined as an ANC > 0.5 x 10(9)/1. No patient who had initial engraftment had late graft failure. Within our study group the risk of graft rejection or graft failure does not appear to be higher than that reported for URD transplants utilizing TBI-containing regimens.
Collapse
Affiliation(s)
- J L Klein
- Division of Bone Marrow Transplantation, Arthur G James Cancer Hospital and Research Institute, Ohio State University, Columbus, USA
| | | | | | | | | | | | | | | | | |
Collapse
|
46
|
Klein JL, Price DA, Fisher M, Coker RJ. Cytomegalovirus infection: a possible cause of recurrent transient neurological dysfunction in advanced HIV infection. AIDS 1996; 10:345-6. [PMID: 8882682] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/02/2023]
|
47
|
Benjamin D, Sharma V, Kubin M, Klein JL, Sartori A, Holliday J, Trinchieri G. IL-12 expression in AIDS-related lymphoma B cell lines. The Journal of Immunology 1996. [DOI: 10.4049/jimmunol.156.4.1626] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/01/2023]
Abstract
Abstract
IL-12 is a 70-kDa heterodimer formed by the 40-kDa heavy chain (p40) and the 35-kDa light chain (p35). Twenty-five Burkitt's lymphoma cell lines (CL) and seven normal lymphoblastoid B CL were studied. The Burkitt's CL included AIDS-associated B CL (AABCL) (7 EBV+/2 EBV-) and non-AABCL (8 EBV+/8 EBV-). Reverse transcription-PCR detected p40 in EBV+ AABCL (7 of 7), EBV+ non-AABCL (3 of 8), and normal lymphoblastoid B CL (6 of 6) but not in EBV- CL (0 of 10). p35 mRNA was detected in 30 of 30 CL. Constitutive secretion of p40 was found in 7 of 7 EBV+ AABCL (range, 341-18,086 pg/ml) and p70 in 3 of 7 EBV+ AABCL (range, 25-197 pg/ml), but in only 1 of 8 EBV+ non-AABCL and 0 of 7 normal lymphoblastoid CL. PMA stimulated p40 secretion in 7 of 7 EBV+ AABCL and p70 secretion in 5 of 7 EBV+ AABCL. PMA also triggered p40 and p70 secretion in 2 EBV+ non-AABCL and in 3 of 7 normal lymphoblastoid CL. No IL-12 secretion was detected in 10 EBV- CL, including EBV- AABCL. The CL produced IL-10, a known inhibitor of IL-12, but anti-IL-10 Abs did not neutralize IL-12. Similarly, neutralizing anti-IFN gamma Abs or IFN gamma did not affect B cell IL-12. For IL-12R studies, reverse transcription-PCR and 125I-IL-12 binding assays were performed. Although all CL tested showed mRNA accumulation for one of the IL-12R components, IL-12 binding sites were detected in only 1 of 30 CL. Our data suggest that: 1) AABCL constitutively secrete large amounts of IL-12, contrasting with low IL-12 production by HIV-1 infected PBMC; 2) lack of IL-12 expression in EBV- AABCL suggests that in vivo exposure of B cells to HIV-1 only does not induce IL-12 secretion and that both HIV-1 and EBV are required; 3) the autocrine-negative effect of IL-10 on IL-12 in monocytes and the enhancing effect of IFN gamma on IL-12 secretion do not apply to B cells derived from AIDS patients.
Collapse
Affiliation(s)
- D Benjamin
- Division of Hematology and Oncology, Arthur G. James Cancer Hospital and Research Institute, Columbus, OH 43210, USA
| | - V Sharma
- Division of Hematology and Oncology, Arthur G. James Cancer Hospital and Research Institute, Columbus, OH 43210, USA
| | - M Kubin
- Division of Hematology and Oncology, Arthur G. James Cancer Hospital and Research Institute, Columbus, OH 43210, USA
| | - J L Klein
- Division of Hematology and Oncology, Arthur G. James Cancer Hospital and Research Institute, Columbus, OH 43210, USA
| | - A Sartori
- Division of Hematology and Oncology, Arthur G. James Cancer Hospital and Research Institute, Columbus, OH 43210, USA
| | - J Holliday
- Division of Hematology and Oncology, Arthur G. James Cancer Hospital and Research Institute, Columbus, OH 43210, USA
| | - G Trinchieri
- Division of Hematology and Oncology, Arthur G. James Cancer Hospital and Research Institute, Columbus, OH 43210, USA
| |
Collapse
|
48
|
Benjamin D, Sharma V, Kubin M, Klein JL, Sartori A, Holliday J, Trinchieri G. IL-12 expression in AIDS-related lymphoma B cell lines. J Immunol 1996; 156:1626-37. [PMID: 8568269] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Subscribe] [Scholar Register] [Indexed: 01/31/2023]
Abstract
IL-12 is a 70-kDa heterodimer formed by the 40-kDa heavy chain (p40) and the 35-kDa light chain (p35). Twenty-five Burkitt's lymphoma cell lines (CL) and seven normal lymphoblastoid B CL were studied. The Burkitt's CL included AIDS-associated B CL (AABCL) (7 EBV+/2 EBV-) and non-AABCL (8 EBV+/8 EBV-). Reverse transcription-PCR detected p40 in EBV+ AABCL (7 of 7), EBV+ non-AABCL (3 of 8), and normal lymphoblastoid B CL (6 of 6) but not in EBV- CL (0 of 10). p35 mRNA was detected in 30 of 30 CL. Constitutive secretion of p40 was found in 7 of 7 EBV+ AABCL (range, 341-18,086 pg/ml) and p70 in 3 of 7 EBV+ AABCL (range, 25-197 pg/ml), but in only 1 of 8 EBV+ non-AABCL and 0 of 7 normal lymphoblastoid CL. PMA stimulated p40 secretion in 7 of 7 EBV+ AABCL and p70 secretion in 5 of 7 EBV+ AABCL. PMA also triggered p40 and p70 secretion in 2 EBV+ non-AABCL and in 3 of 7 normal lymphoblastoid CL. No IL-12 secretion was detected in 10 EBV- CL, including EBV- AABCL. The CL produced IL-10, a known inhibitor of IL-12, but anti-IL-10 Abs did not neutralize IL-12. Similarly, neutralizing anti-IFN gamma Abs or IFN gamma did not affect B cell IL-12. For IL-12R studies, reverse transcription-PCR and 125I-IL-12 binding assays were performed. Although all CL tested showed mRNA accumulation for one of the IL-12R components, IL-12 binding sites were detected in only 1 of 30 CL. Our data suggest that: 1) AABCL constitutively secrete large amounts of IL-12, contrasting with low IL-12 production by HIV-1 infected PBMC; 2) lack of IL-12 expression in EBV- AABCL suggests that in vivo exposure of B cells to HIV-1 only does not induce IL-12 secretion and that both HIV-1 and EBV are required; 3) the autocrine-negative effect of IL-10 on IL-12 in monocytes and the enhancing effect of IFN gamma on IL-12 secretion do not apply to B cells derived from AIDS patients.
Collapse
MESH Headings
- Acquired Immunodeficiency Syndrome/complications
- Acquired Immunodeficiency Syndrome/immunology
- Base Sequence
- Burkitt Lymphoma/metabolism
- Cloning, Molecular
- DNA Primers/chemistry
- Gene Expression
- Humans
- Interferon-gamma/metabolism
- Interleukin-10/metabolism
- Interleukin-12/genetics
- Interleukin-12/metabolism
- Lymphoma, AIDS-Related/complications
- Lymphoma, AIDS-Related/metabolism
- Lymphoma, B-Cell/complications
- Lymphoma, B-Cell/metabolism
- Molecular Sequence Data
- RNA, Messenger/genetics
- Receptors, Interleukin/genetics
- Receptors, Interleukin/metabolism
- Receptors, Interleukin-12
- Tumor Cells, Cultured
Collapse
Affiliation(s)
- D Benjamin
- Division of Hematology and Oncology, Arthur G. James Cancer Hospital and Research Institute, Columbus, OH 43210, USA
| | | | | | | | | | | | | |
Collapse
|
49
|
Gulec SA, Serafini AN, Moffat FL, Vargas-Cuba RD, Sfakianakis GN, Franceschi D, Crichton VZ, Subramanian R, Klein JL, De Jager RL. Radioimmunoscintigraphy of colorectal carcinoma using technetium-99m-labeled, totally human monoclonal antibody 88BV59H21-2. Cancer Res 1995; 55:5774s-5776s. [PMID: 7493345] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/25/2023]
Abstract
Radioimmunoscintigraphy (RIS) using human monoclonal antibodies offers the important clinical advantage of repeated imaging over murine monoclonal antibodies by eliminating the cross-species antibody response. This article reports a Phase I-II clinical trial with Tc-99m-labeled, totally human monoclonal antibody 88BV59H21-2 in patients with colorectal carcinoma. The study population consisted of 34 patients with colorectal cancer (20 men and 14 women; age range, 44-81 years). Patients were administered 5-10 mg antibody labeled with 21-41 mCi Tc-99m by the i.v. route and imaged at 3-10 and 16-24 h after infusion using planar and single-photon emission computed tomographic (CT) techniques. Pathological confirmation was obtained in 25 patients who underwent surgery. Human antihuman antibody (HAHA) titers were checked prior to and 1 and 3 months after the infusion. RIS with Tc-99m-labeled 88BV59H21-2 revealed a better detection rate in the abdomen-pelvis region compared with axial CT. The combined use of both modalities increased the sensitivity in both the liver and abdomen-pelvis regions. Ten patients developed mild adverse reactions (chills and fever). No HAHA response was detected in this series. Tc-99m-labeled human monoclonal antibody 88BV59H21-2 RIS shows promise as a useful diagnostic modality in patients with colorectal cancer. RIS alone or in combination with CT is more sensitive than CT in detecting tumor within the abdomen and pelvis. Repeated RIS studies may be possible, due to the lack of a HAHA response.
Collapse
Affiliation(s)
- S A Gulec
- Division of Nuclear Medicine, University of Miami School of Medicine, Sylvester Comprehensive Cancer Center, Florida 33136, USA
| | | | | | | | | | | | | | | | | | | |
Collapse
|
50
|
Herpst JM, Klein JL, Leichner PK, Quadri SM, Vriesendorp HM. Survival of patients with resistant Hodgkin's disease after polyclonal yttrium 90-labeled antiferritin treatment. J Clin Oncol 1995; 13:2394-400. [PMID: 7666099 DOI: 10.1200/jco.1995.13.9.2394] [Citation(s) in RCA: 35] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/26/2023] Open
Abstract
PURPOSE A follow-up study was initiated of patients with Hodgkin's disease who were treated with yttrium 90-labeled antiferritin. Prescription method, pharmacokinetics, acute and late side effects, and survival were evaluated. METHODS Patients had measurable disease and failed > or = two multiagent chemotherapy regimens previously (N = 44). All patients received 5-mCi indium 111-labeled antiferritin 2 mg intravenously and were scanned repeatedly by gamma camera. In five patients, polyclonal antiferritin (rabbit, pig, or baboon) failed to target the tumor. Thirty-nine patients were injected intravenously with 10-, 20-, 30-, 40-, or 50-mCi yttrium 90-labeled antiferritin 2 to 5 mg. Patients received between one and five cycles. Some patients were supported with 5 x 10(7) autologous bone marrow cells per kilogram. RESULTS Yttrium 90-labeled polyclonal antiferritin does not produce immunologic, pharmacologic, or microbiologic complications in vivo. Bone marrow toxicity is the only side effect observed. Overall response rate is 20 of 39, or 51%. Two patients had stable disease. A significant positive correlation is found between blood radioactivity level 1 hour after radioimmunoconjugate administration and subsequent response of Hodgkin's disease. A dosage in millicuries per kilogram provides a higher positive correlation with blood radioactivity levels 1 hour after administration than a dosage in millicuries per square meter of body-surface area or in total millicuries. Fifty percent of patients survive for > or = 6 months. CONCLUSION The low-dose protein used (2 to 5 mg) indicates that the high response rate is due to radiation and not to immunologic effects of the antibody. High-activity administrations followed by bone marrow transplantation are not required for tumor response. The therapeutic ratio of radiolabeled antiferritin is higher than the therapeutic ratio observed in most phase I studies of chemotherapeutic agents. This analysis does not identify a superior mode of treatment for patients with end-stage Hodgkin's disease. However, in a heavily pretreated patient population, prolonged survival is observed after relatively inexpensive treatment. Preclinical research with yttrium 90-labeled antiferritin indicates that significant increases in tumor dose can be obtained in the future without an increase in normal tissue toxicity.
Collapse
Affiliation(s)
- J M Herpst
- Division of Radiation Oncology, Johns Hopkins Hospital, Baltimore, MD, USA
| | | | | | | | | |
Collapse
|